StrengthTalking point
Profit outpacing revenue
Profit grew 33.1% while revenue grew 15.8%, so the company kept more of each rupee of revenue as profit.
Importance 64 / 95 · growth
Apollo Hospitals Enterprises · Research view
Apollo Hospitals Enterprises Ltd.
NSE: APOLLOHOSPBSE: 508869ISIN INE437A01024Face value ₹5consolidated
₹8,116
−6.73% · 2026-10-01 · 52-wk ₹6,794–₹9,060
Financials to FY2026 · 5 years of history · prices to 2026-10-01consolidatedstandalone
Section 02 · Synthesis
What stands out?
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
StrengthConcernWatchContext
StrengthTalking point
Returns at a multi-year high
ROE of 21.5% is the highest in 4 years (prior range 13.5% to 18.8%).
Importance 56 / 95 · profitability
StrengthTalking point
Compounding revenue
Revenue compounded at 14.5% a year over 4 years (₹14,663 → ₹25,229).
Importance 55 / 95 · growth
Section 03 · The company
Who is this company?
Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.
- Market cap
- ₹1.17 L cr
- FY2026 revenue
- ₹25,229 cr
- FY2026 net profit
- ₹2,003 cr
- Net worth
- ₹9,975 cr
- Total debt
- ₹5,659 cr
- EPS (basic)
- ₹135.04
- Listed
- NSE · BSE
- Reporting
- Ind-ASApr–Mar
Peer set used on this page: 3 hospital.
Section 04 · Business performance
Is the business growing?
RevenueNet profit
Strength
Profit grew 33.1% while revenue grew 15.8%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
- Revenue growth per year
- +14.5%over 4 years
- Revenue growth
- +15.8%vs last year
- Net profit growth
- +33.1%vs last year
- Change in net profit since FY22
- +81%
Revenue compounded at 14.5% a year over 4 years (₹14,663 → ₹25,229).
Net profit grew 33.1% year on year (FY2025 → FY2026).
Revenue grew 15.8% year on year (FY2025 → FY2026).
Section 05 · Recent activity
What changed recently?
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Strength
Q1 FY27 net profit was ₹610 cr, up 38.4% from ₹441 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Strength
Q1 FY27 revenue was ₹7,044 cr, up 20.6% from ₹5,842 cr in Q1 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Strength
Q1 FY27 EBIT was ₹906 cr, up 33.7% from ₹677 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
A. Quarterly results
RevenueNet profit
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q2 FY25 | 5,589 | — | 396 | — | 7.1% |
| Q3 FY25 | 5,527 | +13.9% | 379 | +49.1% | 6.9% |
| Q4 FY25 | 5,592 | +13.1% | 415 | +60.4% | 7.4% |
| Q1 FY26 | 5,842 | +14.9% | 441 | +39.8% | 7.5% |
| Q2 FY26 | 6,304 | +12.8% | 494 | +24.8% | 7.8% |
| Q3 FY26 | 6,477 | +17.2% | 516 | +36.1% | 8.0% |
| Q4 FY26 | 6,606 | +18.1% | 551 | +33.0% | 8.3% |
| Q1 FY27 | 7,044 | +20.6% | 610 | +38.4% | 8.7% |
B. TTM snapshot
Trailing twelve months to 30 Jun 2026 · sum of the last 4 contiguous quarters
- Revenue
- ₹26,430 crTTM
- EBITDA
- ₹4,210 crTTM
- EBIT
- ₹3,313 crTTM
- PBT
- ₹2,832 crTTM
- Net profit
- ₹2,172 crTTM
C. Corporate actions
14 Aug 2026DividendFinal Dividend - Rs. - 10.0000 — ₹10.00/share
16 Feb 2026DividendInterim Dividend - Rs. - 10.0000 — ₹10.00/share
19 Aug 2025DividendFinal Dividend - Rs. - 10.0000 — ₹10.00/share
14 Feb 2025DividendInterim Dividend - Rs. - 9.0000 — ₹9.00/share
16 Aug 2024DividendFinal Dividend - Rs. - 10.0000 — ₹10.00/share
20 Feb 2024DividendInterim Dividend - Rs. - 6.0000 — ₹6.00/share
18 Aug 2023DividendFinal Dividend - Rs. - 9.0000 — ₹9.00/share
24 Feb 2023DividendInterim Dividend - Rs. - 6.0000 — ₹6.00/share
18 Aug 2022DividendDividend - Rs. - 11.7500 — ₹11.75/share
18 Aug 2021DividendDividend - Rs. - 3.0000 — ₹3.00/share
17 Sept 2020DividendFinal Dividend - Rs. - 2.7500 — ₹2.75/share
25 Feb 2020DividendInterim Dividend - Rs. - 3.2500 — ₹3.25/share
12 Sept 2019DividendDividend - Rs. - 6.0000 — ₹6.00/share
12 Sept 2018DividendDividend - Rs. - 5.0000 — ₹5.00/share
7 Sept 2017DividendDividend - Rs. - 6.0000 — ₹6.00/share
22 Mar 2016DividendInterim Dividend - Rs. - 6.0000 — ₹6.00/share
30 Jul 2015DividendDividend - Rs. - 5.7500 — ₹5.75/share
13 Aug 2014DividendDividend - Rs. - 5.7500 — ₹5.75/share
25 Jul 2013DividendDividend - Rs. - 5.5000 — ₹5.50/share
26 Jul 2012DividendDividend - Rs. - 4.0000 — ₹4.00/share
7 Jul 2011DividendDividend - Rs. - 3.7500 — ₹3.75/share
2 Sept 2010Stock splitStock Split From Rs.10/- to Rs.5/- — 10:5
15 Jul 2010DividendDividend - Rs. - 7.0000 — ₹7.00/share
20 Aug 2009DividendDividend - Rs. - 6.5000 — ₹6.50/share
11 Aug 2008DividendDividend - Rs. - 6.0000 — ₹6.00/share
Section 06 · Business performance
Is it becoming more profitable?
EBITDA marginNet margin
Strength
ROE of 21.5% is the highest in 4 years (prior range 13.5% to 18.8%).
Rule ROE_AT_MULTI_YEAR_HIGH
- EBITDA margin now
- 15.7%
- 5-year range
- 12.9–15.7%
- ROE FY2026
- 21.5%
- ROCE FY2026
- 20.9%
ROE of 21.5% is well above the hospital median of 14.3%.
EBITDA margin of 15.7% is below the hospital median of 23.4%.
ROE improved from 18.8% to 21.5% year on year.
Section 07 · Financial health
Is financial health improving?
Net worth (shareholders' funds)
Strength
Net worth compounded at 14.0% a year over 4 years (₹5,899 → ₹9,975).
Rule NET_WORTH_COMPOUNDING
Operating cash flowNet profit
- Total debt
- ₹5,659 cr
- Operating cash flow ÷ net profit
- 1.43×FY2026
- Free cash flow
- ₹925 cr
- Current ratio
- 1.06×
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.43×).
Free cash flow has been positive in 5 of the last 5 years.
Section 08 · Relative position
How does it compare with peers?
Ranked against 3 hospital (FY2026, consolidated). No peer-relative rule fired for this company.
Revenue growth
APOLLOHOSP · 3rd of 3 · set median 17.3%
EBITDA margin
APOLLOHOSP · 3rd of 3 · set median 23.4%
Return on equity
APOLLOHOSP · 1st of 3 · set median 14.3%
P/E ratio
APOLLOHOSP · 1st of 3 · set median 55.4×
- P / E
- 53.7×TTM to Jun 26
- P / B
- 11.7×latest book
- P / S
- 4.4×TTM sales
- Earnings yield
- 1.9%TTM to Jun 26
On the trailing twelve months. Last full year: P/E 58.3× · P/S 4.6× · ROE 21.5%.
Section 09 · The stock
How has the stock performed?
Context
Over 4 years profit (15.9% a year) and the stock (16.5% a year) compounded at roughly the same rate.
Rule STOCK_TRACKED_EARNINGS
- 1-year return
- +9.1%
- 3-year return
- +58.0%
- 5-year return
- +82.0%
- From 52-wk high
- −10.4%
Section 10 · Technical data
What does the technical data say?
Price-action indicators as of 2026-10-01. Secondary to the fundamentals above — included for timing context, not as a signal.
- vs 50-day avg
- Below₹8,825
- vs 200-day avg
- Above₹7,998
- RSI (14)
- 29.0oversold
- MACD histogram
- -52.6
- From 52-wk high
- −10.4%
- From 52-wk low
- +19.5%
- 30-day volatility
- 25.7%ann.
- 6-month return
- +9.5%
Section 11 · Open questions
What should I investigate further?
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
- ConcernThinner margins than peersEBITDA margin of 15.7% is below the hospital median of 23.4%.MARGIN_BELOW_PEER_MEDIAN · conviction 47
Data coverage is complete — 5 years of financials (FY2022–FY2026), full P&L, balance sheet and cash-flow statement, sector metrics fully mapped.
Section 12 · Reference
The numbers
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 14,663 | 16,612 | 19,059 | 21,794 | 25,229 |
| Total income | 14,741 | 16,703 | 19,166 | 21,994 | 25,420 |
| EBITDA | 2,263 | 2,140 | 2,497 | 3,222 | 3,961 |
| Profit before tax | 1,578 | 1,144 | 1,363 | 2,006 | 2,616 |
| Net profit | 1,108 | 845 | 935 | 1,505 | 2,003 |
| EPS (₹) | 73.4 | 57.0 | 62.5 | 209.3 | 135.0 |
| Net worth | 5,899 | 6,531 | 7,321 | 8,653 | 9,975 |
| Total debt | 2,636 | 2,710 | 3,162 | 5,275 | 5,659 |
| Operating cash flow | 1,616 | 1,377 | 1,920 | 2,136 | 2,856 |
| Free cash flow | 958 | 253 | 785 | 439 | 925 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 13.3 | 14.7 | 14.3 | 15.8 |
| Profit growth YoY | — | -23.8 | 10.7 | 61.0 | 33.1 |
| Profitability | |||||
| EBITDA margin % | 15.4 | 12.9 | 13.1 | 14.8 | 15.7 |
| Net margin % | 7.5 | 5.1 | 4.9 | 6.8 | 7.9 |
| Return on equity % | 18.8 | 13.6 | 13.5 | 18.8 | 21.5 |
| Return on capital % | 19.5 | 17.2 | 18.4 | 20.2 | 20.9 |
| Leverage & cash | |||||
| Debt to equity | 0.45 | 0.41 | 0.43 | 0.61 | 0.57 |
| Cash flow ÷ profit | 1.46 | 1.63 | 2.05 | 1.42 | 1.43 |
| Current ratio | 1.73 | 1.30 | 1.13 | 1.54 | 1.06 |